http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016108099-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e56616766a93e5247ecc15446aee157 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 |
| filingDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_767d9de6188dd8798bc49dcb1a8336e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ece5f66f0a24ba1113e23b596decd935 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94d141de9cb5612153c9a232400f476b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_297253741469a360b841c5b553d63e93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c05a8d1a6a6e4851035a1b496b326cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a686edc803dfb49a41bd37e72cb18bf6 |
| publicationDate | 2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016108099-A2 |
| titleOfInvention | Method for determining the best treatment for cancer patients, comprising the culture and expansion of cells present in ascites fluid of peritoneal, pleural, peritoneal lavage or systemic lavage origin |
| abstract | The invention relates to a diagnosis method which is used outside the human or animal body and which can be used to identify and/or predict the best cancer treatment for a patient, said method comprising: i) depositing a sample of ascites fluid from a patient in a centrifuge and centrifuging the sample in order to obtain a first phase containing cells and a second phase corresponding to cell-free fluid; ii) analysing the second phase in order to check for the presence of at least 10 platelets per ml; iii) expanding the cells present in the first phase in a culture medium until 80% confluence is obtained; iv) selecting the cells expanded in step (iii), performing a cell dissociation step with a proteolytic enzyme or using a calcium chelating agent and subsequently, from the dissociated cells, determining molecular and/or cellular markers, in order to confirm the presence of a mixed cell population; and v) determining the best treatment for patients by: a) adding a dose of a chemotherapy drug to the cells from step (iv); b) using a viability assay to measure the degree of toxicity of each drug in the cells; c) repeating steps (a) and (b) with different chemotherapy drugs; and d) analysing the results obtained, whereby a response below 30% toxicity reflects resistance to treatment, a response above 30% toxicity corresponds to intermediate sensitivity to treatment, and a response above 50% toxicity reflects a high probability of response to treatment. |
| priorityDate | 2014-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.